By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#147-Hussein Yassine, M.D.: Deep dive into the “Alzheimer’s gene” (APOE), brain health, and omega-3s
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
CHAPTERS
- 0:11 – 3:56
Episode Preview and Guest Introduction
Peter Attia introduces Dr. Hussein Yassine and his lab's focus on lipid metabolism, nutrition, cognition and the ApoE4 allele. He outlines the episode's arc from brain biology through ApoE to omega-3s, and warns that the state of knowledge is frustratingly limited.
- •Yassine's lab studies lipid metabolism and nutrition in relation to Alzheimer's risk and ApoE4
- •The episode is framed as core coursework on brain architecture and energy before turning to ApoE
- •Attia warns listeners they may come away frustrated by how little is known
- •The discussion moves from ApoE isoforms to a side tangent on EPA in cardiovascular disease, then to DHA in the brain
- 3:56 – 5:30
Yassine's Path and Why ApoE Genotype Matters
Yassine describes his training in Lebanon and the US, and his move from blood lipids to brain lipids. He notes how often people who learn they are E4 carriers from consumer testing contact him.
- •Yassine grew up in Beirut, did medical school there, then residency and an endocrinology fellowship in the US
- •A family history of heart disease and diabetes led him to lipid disorders
- •He switched from studying blood lipids to brain lipids
- •People who find out they carry E4 through 23andMe call him about what it means
- 5:30 – 13:08
Brain Architecture: Cells, Blood-Brain Barrier, and CSF
Yassine explains that the brain is mostly a lipid organ and describes neurons, astrocytes and microglia. He then covers the blood-brain barrier and the CSF drainage system that clears byproducts such as A-beta.
- •Neurons fire; astrocytes and microglia provide energy support and immune cleanup
- •The blood-brain barrier is built from endothelial cells with tight junctions, pericytes and mural cells
- •CSF acts as the brain's sewage system, driven by the choroid plexus
- •A-beta peptides leak into the CSF and are cleared via the blood to the liver
- 13:08 – 19:47
Why the Brain Is So Lipid-Rich
Attia discusses CSF disorders and the bloodless look of the brain, then asks why brain cells need so much lipid compared with a cardiac myocyte. Yassine explains the brain's function as an electrical wiring system that depends on myelin and synaptic membranes.
- •Brain function is signaling, so it requires lipid-rich myelin and synaptosomes
- •Depolarization depends on a specific lipid membrane environment
- •Cardiac myocytes are mechanical cells that rely on cytoskeletal proteins like actin and myosin and need fewer lipids
- •The brain is about 2% of body weight but uses roughly 20% of energy
- 19:47 – 27:40
How the Brain Uses Energy: GLUT1, Lactate, and Ketones
Yassine describes how the brain extracts glucose through GLUT1 rather than insulin-dependent GLUT4, and how GLUT1 is regulated to protect the brain. He also covers astrocyte-to-neuron lactate shuttling, the brain's poor use of fat, and ketone use during fasting.
- •GLUT1 at the blood-brain barrier is down-regulated in hyperglycemia and up-regulated in hypoglycemia
- •In Alzheimer's, barrier leakage is associated with loss of GLUT1
- •Astrocytes convert glucose to lactate and pass it to neurons
- •The brain does not store fat and burns it only in crises, at the cost of oxidative stress
- •With prolonged fasting the brain extracts ketone bodies
- 27:40 – 38:15
ApoE in the Periphery: The Lipoprotein Conductor
Using an orchestra analogy, Yassine explains ApoE as an exchangeable apolipoprotein that, along with ApoC3, regulates lipoprotein clearance. He explains why ApoE concentration is far less informative than ApoB or ApoA1.
- •ApoE and ApoC3 are exchangeable and move between lipoprotein classes, unlike ApoB and ApoA1
- •ApoC3 keeps particles in circulation while ApoE promotes clearance via receptors like LRP1
- •Measuring ApoE concentration says little because its function depends on which particle carries it
- •ApoE binds receptors through its N-terminus and lipids through its C-terminus
- 38:15 – 43:47
ApoE's Role in the Brain
In the brain, ApoE supports astrocytes and crosstalk between cell types, helps repair after injury, and regulates inflammation. Unlike ApoB it recycles rather than being degraded, and Yassine's research suggests ApoE4 may cross the blood-brain barrier through LRP1.
- •Brain apolipoprotein particles differ from plasma LDL and VLDL
- •ApoE moves cholesterol from astrocytes to neurons and influences glial inflammation
- •ApoE rises sharply after nerve damage
- •ApoE escapes degradation and recycles in and out of cells
- •ApoE4 may slip through endothelial LRP1 into the brain
- 43:47 – 53:31
Evolutionary Origins of the ApoE Isoforms
Yassine explains that E4 is the ancestral variant and that its pro-inflammatory strength likely helped survival against infection and parasites. As lifespans lengthened and environments and diets changed, E3 and E2 became favored, and E4 may have been matched to a diet higher in fat and fish.
- •E4 aggregates more and drives a stronger inflammatory response, which helped against sepsis and parasites
- •E4 carriers often did not live long enough to develop Alzheimer's
- •Migration to plant-based diets may have favored E3 and E2
- •E4 weakens GLUT1 at the blood-brain barrier, a hypothesis tied to ancestral fat-reliant diets
- 53:31 – 1:03:12
E4 and Alzheimer's Risk: Discovery, Hazard, and Ethnic Variation
Yassine recounts how Allen Roses at Duke linked ApoE4 to Alzheimer's in the late 1980s despite resistance from the amyloid hypothesis. He gives risk magnitudes for one and two copies and explains how linkage disequilibrium and gene-environment interactions such as diabetes explain varying risk.
- •Roses's studies tied E4 to late-onset Alzheimer's
- •Two copies raise risk about 12-fold and one copy about two to four-fold
- •E2 is protective, and 2-4 carriers behave variably
- •Risk differs by ethnicity partly because of co-inherited variants near ApoE such as TOM40
- •In a Colombian study, E4 combined with diabetes raised risk, while E4 alone in lean, healthy people did little
- 1:03:12 – 1:13:34
E4, Diet, Aging, and the Multiple-Hit Model
Discussion turns to how E4 impairs GLUT1 and omega-3 transporters and whether diet should be matched to genotype. Yassine describes E4 risk as an aging-related disease requiring second and third hits, with energy, inflammation and vascular leakage hypotheses that are not mutually exclusive.
- •E4 reduces GLUT1 function and also affects omega-3 transporters
- •Type 2 diabetes is a syndrome, and E4 may itself contribute to insulin resistance
- •Younger E4 carriers are typically fully functional, and only a subset develop disease with age
- •Traumatic brain injury, diabetes and other genetic hits worsen outcomes
- •Energy, neuroinflammation and blood-brain barrier leakage are overlapping hypotheses
- 1:13:34 – 1:22:04
Omega-3 Basics: DHA, EPA, and Dietary Sources
Yassine explains what DHA and EPA are, why the brain is rich in polyunsaturated fats, and why dietary intake matters since conversion from ALA is minimal. He notes that supplement trials have been conflicting and that the sources of omega-3s vary.
- •DHA is the predominant omega-3 in the brain, while EPA is less abundant but more anti-inflammatory
- •Conversion from ALA to DHA and EPA is thought to be only about 0.5%, and no more than 5%
- •US DHA intake averages around 100 mg per day
- •Supplement trials are conflicted and the products differ in form and dose
- •Benefit may arise from avoiding a deficiency rather than from high intake
- 1:22:04 – 1:30:59
REDUCE-IT vs. STRENGTH: EPA and Cardiovascular Events
Attia and Yassine review the REDUCE-IT trial of four grams of EPA and the criticism of its mineral oil placebo. They then contrast it with the STRENGTH trial, which showed no benefit against corn oil, and discuss possible mechanisms and the gap between a drug and a supplement.
- •REDUCE-IT gave 4 g EPA to high-risk patients with high triglycerides and showed a large reduction in events
- •The mineral oil placebo raised the question of whether the placebo caused harm
- •STRENGTH, using mostly EPA against corn oil, showed essentially no difference
- •Possible explanations include dose, EPA:DHA ratio, patient selection, and trial duration
- •Yassine suggests a local anti-inflammatory effect on plaques as one plausible mechanism
- 1:30:59 – 1:42:23
DHA Deficiency, Brain Development, and the Slow Turnover of Brain Lipids
Yassine contrasts the chronic course of Alzheimer's with cardiovascular events and shows that DHA deficiency is clearly harmful in development, as seen in mouse and infant formula evidence. He explains that brain lipid pools turn over slowly, which makes short supplementation trials unlikely to show an effect.
- •DHA-deprived mouse pups developed microcephaly and fewer synapses
- •Infant formula is fortified with DHA and AA following studies from the 1990s
- •The effects of low omega-3 intake between ages six and 60 are unclear
- •Blood DHA changes over three to six weeks, while brain membrane DHA persists much longer
- •Most trials last three to six months, so any effect may be gut or inflammatory
- 1:42:23 – 1:50:38
DHA in E4 Carriers: Critical Window and the PREVENT-E4 Trial
Yassine reports that younger E4 carriers take up more DHA in the brain, while uptake declines after about 55 to 70 as the blood-brain barrier deteriorates. A 2010 trial of DHA in mild Alzheimer's showed no benefit in E4 carriers, and his team's PREVENT-E4 trial aims to test high-dose DHA before dementia.
- •PET studies showed greater brain DHA uptake in younger E4 carriers than in non-carriers
- •A Finnish epidemiology study linked high fish omega-3 intake in E4 carriers to less disease later
- •DHA uptake falls between about 55 and 70, around the time GLUT1 and the blood-brain barrier are compromised
- •In the 2010 DHA trial in mild Alzheimer's, E4 carriers had no response while non-carriers appeared to improve
- •PREVENT-E4 gives 2 g of DHA to E4 carriers aged 55 to 70 and began in 2019 before a COVID pause
- 1:50:38 – 1:59:05
Biomarkers, Late-Stage E4 Brain Changes, and Ketones
Attia and Yassine discuss the lack of surrogate brain biomarkers and the difficulty of lifelong trials, and weigh the asymmetry of risk in acting without trial evidence. Yassine describes upregulated phospholipase A2 in E4 Alzheimer's brains and explains why ketone interventions may fail in late-stage E4 disease.
- •A trusted brain biomarker could allow faster prevention trials, as LDL did for cardiology
- •Attia suggests weighing the downside of doing nothing against that of taking DHA
- •Calcium-dependent phospholipase A2 is hyperactivated in E4 Alzheimer's brains and not in non-E4 brains with similar dementia
- •This may represent the brain digesting its own membranes for ATP, with inflammation and oxidative stress as side effects
- •E4 carriers with disease were less likely to benefit from ketone supplementation, possibly due to impaired transport
- 1:59:05 – 2:06:30
Practical Recommendations for E4 Carriers and Closing
Yassine says he does not recommend omega-3 supplements because evidence is lacking, but does recommend at least one serving of fatty fish per week. He adds that exercise, blood pressure control and education are associated with lower risk in E4 carriers, and Attia closes the conversation.
- •No omega-3 supplement recommendation without high-quality evidence
- •At least one weekly serving of fatty fish for E4 carriers
- •Exercise was linked to less amyloid buildup in E4 carriers in an imaging study
- •Education and blood pressure control were associated with protection from dementia
- •Modifying E4 risk often means modifying its vascular effects
